Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI) - SC Ematologia
Welcome,         Profile    Billing    Logout  
 43 Trials 
80 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zaja, Francesco
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Hourglass May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL
Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting
3
300
Europe, RoW
R-pola-mini-CHP, R-mini-CHOP
Nordic Lymphoma Group, Roche Pharma AG
DLBCL, Diffuse Large B Cell Lymphoma
12/25
12/28
NCT04168502 / 2019-003871-20: Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

Recruiting
3
414
Europe
Gemtuzumab Ozogamicin
Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Pfizer S.R.L.
Acute Myeloid Leukemia
04/25
04/27
BRUIN CLL-321, NCT04666038: Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
05/25
08/26
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
05/25
04/27
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
NCT03552692 / 2017-004630-29: Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma

Terminated
2
22
Europe
Venetoclax, ABT-199/GDC-0199
Fondazione Italiana Linfomi - ETS
T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory
03/20
02/23
FIL_KLIMT, NCT03891355 / 2018-000540-25: Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL

Active, not recruiting
2
16
Europe
Carfilzomib, Lenalidomide, Dexamethasone
Fondazione Italiana Linfomi ONLUS, CELGENE, AMGEN
Mantle Cell Lymphoma
12/20
12/22
NCT04251065 / 2018-002644-91: Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH

Terminated
2
8
Europe
Daratumumab, Darzalex
Fondazione Italiana Linfomi - ETS, Janssen
Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma
12/21
11/22
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Active, not recruiting
2
75
Europe
Ibrutinib, IMBRUVICA (commercial name)
Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.
DLBCL
07/24
07/27
Phoenix, NCT05924100 / 2021-001538-20: Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD

Recruiting
2
22
Europe
Luspatercept Injection [Reblozyl]
Associazione Qol-one, Celgene BMS
Myelodysplastic Syndromes, Del(5Q), Anemia, Transfusion-dependent Anemia
12/24
12/29
MALIBU, NCT03697512 / 2018-002364-44: Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

Active, not recruiting
2
175
Europe
Ibrutinib, Rituximab
International Extranodal Lymphoma Study Group (IELSG), Janssen-Cilag AG, F. Hoffmann La Roche Ltd, Janssen Pharmaceutica NV
Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma
06/27
06/27
NCT04278924 / 2019-004103-12: A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

Completed
2
41
Europe, Japan, US, RoW
Placebo, TAK-079
Takeda
Primary Immune Thrombocytopenia
04/24
04/24
FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

Recruiting
2
49
Europe
Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C)), Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)
Fondazione Italiana Linfomi - ETS
Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
04/26
04/29
EPCORE DLBCL-3, NCT05660967 / 2021-005744-29: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Recruiting
2
180
Europe, Japan, US, RoW
Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid®
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
01/26
07/27
TALIM, NCT06880601: Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma

Not yet recruiting
2
52
NA
Teclistamab
Gruppo Italiano Malattie EMatologiche dell'Adulto
Multiple Myleoma, Multiple Myeloma in Relapse, Multiple Myeloma Refractory
11/29
11/29
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Withdrawn
2
150
Europe
R-DHAP, Pola-R-DHAP
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
01/29
01/29
FIL_A-BEGEV, NCT05300282: Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

Recruiting
1/2
122
Europe
Atezolizumab, BEGEV, Bendamustine, Gemcitabine, Vinorelbine
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Relapsed or Refractory Hodgkin's Lymphoma
04/27
04/30
NCT04454580: Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy

Recruiting
N/A
15
Europe
Venetoclax, Azacitidine, Decitabine
Ospedale Maggiore Di Trieste
Acute Myeloid Leukemia, Adult, Hypomethylating Agents, Venetoclax
09/20
09/20
ICI-RT-1, NCT04419441: Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma

Recruiting
N/A
12
Europe
Immune checkpoint inhibitor, radiotherapy
Ospedale Maggiore Di Trieste
Hodgkin Lymphoma, Immune Checkpoint Inhibitor, Radiotherapy
09/20
09/20
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting
N/A
250
Europe
Ospedale di Circolo - Fondazione Macchi
SARS-CoV-2 Infection, Hematological Malignancies
10/22
10/22
ITP0918, NCT03465020: Investigation on a Dynamic Cohort of Italian Patients With Active ITP

Recruiting
N/A
861
Europe
Observation
Gruppo Italiano Malattie EMatologiche dell'Adulto, Hematology Project Foundation
Idiopathic Thrombocytopenic Purpura
07/23
07/23
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Recruiting
N/A
80
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
03/25
03/25
GIMEMA, NCT04867915: Study on the Diagnosis and Management of CLL in Italy by

Recruiting
N/A
12500
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, MBL-CLL - Monoclonal B-Cell Lymphocytosis Chronic Lymphocytic Leukaemia-Type
10/26
10/26
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting
N/A
1500
Europe
"novel" MAB (alone or in combination)
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Non-Hodgkin Lymphoma, B-cell
10/38
10/38
Fozza, Claudio
NCT04168502 / 2019-003871-20: Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

Recruiting
3
414
Europe
Gemtuzumab Ozogamicin
Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Pfizer S.R.L.
Acute Myeloid Leukemia
04/25
04/27
ACROBAT, NCT04184505 / 2019-003997-25: Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS

Recruiting
3
274
Europe
Azacitidine, AZA, Standard Chemotherapy, STD CHT, Allogeneic stem cell transplantation, HSCT
Gruppo Italiano Malattie EMatologiche dell'Adulto, AIFA - Italian Medicines Agency, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus
High-risk MDS
03/24
03/24
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
1621-QLG-LG, NCT03755856: Long-term Outcomes for Acute Myeloid Leukemia Patients

Recruiting
N/A
343
Europe, RoW
Questionnaire
Gruppo Italiano Malattie EMatologiche dell'Adulto, European Organisation for Research and Treatment of Cancer - EORTC
Acute Myeloid Leukemia
06/21
12/22
CML1012, NCT01752062: Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors

Recruiting
N/A
148
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Myeloid Leukemia, Pregnancy
12/22
12/22
GIMEMA 2320, NCT04589728: Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96

Recruiting
N/A
104
Europe
Venetoclax plus HMA
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia
12/22
12/23
NCT05819528: Primary Cardiac Lymphoma: Italian Multicenter Experience

Recruiting
N/A
43
Europe
Fondazione Italiana Linfomi - ETS
Primary Cardiac Lymphoma
04/26
06/26
NCT04627090: LCH in Adults: a Collaborative, Prospective-retrospective, Observational Study

Recruiting
N/A
186
Europe
Data collection
Gruppo Italiano Malattie EMatologiche dell'Adulto
Langerhans Cell Histiocytosis
03/24
03/24
NCT04460950: Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms

Recruiting
N/A
237
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia, Familial Acute Myeloid Leukemia, Myelodysplastic Syndromes
03/25
03/25
CLARITY, NCT03190525: Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma

Recruiting
N/A
520
Europe
Quality of life questionnaires
Gruppo Italiano Malattie EMatologiche dell'Adulto
Multiple Myeloma
12/24
12/24
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting
N/A
1500
Europe
"novel" MAB (alone or in combination)
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Non-Hodgkin Lymphoma, B-cell
10/38
10/38
Arcari, Annalisa
RENOIR, NCT02390869 / 2012-003392-18: Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

Active, not recruiting
3
128
Europe
R2-MANT, Rituximab and Lenalidomide (R2), R-MANT, Rituximab (R)
Fondazione Italiana Linfomi - ETS
Lymphoma, Follicular
01/23
08/27
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
FIL_Copa-RB, NCT04433182 / 2019-004898-63: Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

Terminated
2
37
Europe
Copanlisib, ALIQOPA
Fondazione Italiana Linfomi - ETS
Diffuse Large B-cell Lymphoma
12/24
12/24
FIORELLA, NCT03495960 / 2016-003116-12: Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System

Completed
2
72
Europe
Rituximab, Methotrexate, Procarbazine, Lenalidomide, Radiotherapy, Temozolomide
International Extranodal Lymphoma Study Group (IELSG)
Primary Central Nervous System Lymphoma
12/24
12/24
FIL_MOZART, NCT06492837: Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Not yet recruiting
2
56
Europe
Mosunetuzumab in combination with Zanubrutinib, LUNSUMIO in combination with BRUSINKA
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
09/28
09/33
EPCORE DLBCL-3, NCT05660967 / 2021-005744-29: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Recruiting
2
180
Europe, Japan, US, RoW
Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid®
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
01/26
07/27
FIL_RICCO, NCT06835530: A Combination of Rituximab and CC-99282 As Front-line Therapy for Older Frail Patients with Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated with a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Not yet recruiting
2
47
Europe
Rituximab + Golcadomide (CC-99282)
Fondazione Italiana Linfomi - ETS
Diffuse Large B Cell Non-Hodgkin Lymphoma
04/30
04/30
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Withdrawn
2
150
Europe
R-DHAP, Pola-R-DHAP
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
01/29
01/29
LH_BIO, NCT06822855: Changing Paragidms in the Prognostic Assessment of Hodgkin Lymphoma

Recruiting
N/A
755
Europe
Azienda Unità Sanitaria Locale Reggio Emilia
Classical Hodgkin Lymphoma, Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory
12/26
12/26
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Recruiting
N/A
80
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
03/25
03/25
NCT06156774: SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

Recruiting
N/A
130
Europe
Chimeric Antigen Receptor T-cells (CAR-T) therapy
Fondazione Italiana Linfomi - ETS, Kite, A Gilead Company
Non-hodgkin Lymphoma,B Cell
07/26
07/26
FIL_FOLL-BIO, NCT05816850: Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial

Recruiting
N/A
654
Europe
EZH2 mutations/CNAs by droplet digital PCR (ddPCR), EZH2-derived gene expression signature by RNA-Seq
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
06/25
06/26
NCT05524298: Quality of Life on Elderly Patients with Low Grade Non-Hodgkin Lymphoma

Recruiting
N/A
150
Europe
Fondazione Italiana Linfomi - ETS
Low Grade Non-Hodgkin's Lymphoma, Adult
02/25
02/25
NCT03552003: Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis

Recruiting
N/A
400
Europe
Treatment for clinical practise
Fondazione Italiana Linfomi ONLUS
Classical Hodgkin Lymphoma
01/26
01/26
NCT05934084: Lifestyles Implemented-Survivorship Care Plan in Lymphoma Survivors

Recruiting
N/A
552
Europe
Lifestyles Implemented-Survivorship Care Plan (LS-SCP)
Fondazione Italiana Linfomi - ETS
Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL)
02/26
02/26
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting
N/A
1500
Europe
"novel" MAB (alone or in combination)
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Non-Hodgkin Lymphoma, B-cell
10/38
10/38
Ferreri, Andres
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Hourglass May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL
Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting
3
300
Europe, RoW
R-pola-mini-CHP, R-mini-CHOP
Nordic Lymphoma Group, Roche Pharma AG
DLBCL, Diffuse Large B Cell Lymphoma
12/25
12/28
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
05/25
04/27
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Active, not recruiting
2
75
Europe
Ibrutinib, IMBRUVICA (commercial name)
Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.
DLBCL
07/24
07/27
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Active, not recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
01/25
07/29
NCT06854653: A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

Recruiting
2
115
Europe, US, RoW
PTX-100
Prescient Therapeutics, Ltd.
CTCL
01/28
06/28
ALPHA-2, NCT04416984: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Recruiting
1/2
160
Europe, Canada, US, RoW
ALLO-501A, ALLO-647, Fludarabine, Cyclophosphamide
Allogene Therapeutics
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
01/25
05/29
2018-523-00US1, NCT03779113: An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

Active, not recruiting
1
140
Europe, US
HMPL-523
Hutchmed
Non Hodgkin Lymphoma
12/24
01/26
NCT05365659: IKS03 in Patients with Advanced B Cell Non-Hodgkin Lymphomas

Recruiting
1
140
Europe, Canada, US, RoW
IKS03
Iksuda Therapeutics Ltd.
B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, B-cell Lymphoma
09/25
09/27
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Recruiting
N/A
80
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
03/25
03/25
NCT06156774: SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

Recruiting
N/A
130
Europe
Chimeric Antigen Receptor T-cells (CAR-T) therapy
Fondazione Italiana Linfomi - ETS, Kite, A Gilead Company
Non-hodgkin Lymphoma,B Cell
07/26
07/26
Montefusco, Vittorio
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
DEDALO, NCT04124497 / 2018-002090-21: A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients

Active, not recruiting
2
45
Europe
Daratumumab, Darzalex, Pomalidomide, Imnovid, Dexamethasone
Fondazione EMN Italy Onlus, Janssen Pharmaceutica NV, Celgene International II
Multiple Myeloma, Deletion 17P Syndrome
07/25
07/25
NCT06682637: Melflufen for Elderly Patients With Relapsed Myeloma

Withdrawn
2
30
Europe
Melflufen, Dexamethasone
Fondazione EMN Italy Onlus
Relapse Multiple Myeloma
03/25
03/25
TAID, NCT04816968: Antibiotics Continuous Infusion at Home

Not yet recruiting
1
50
Europe
Cefepime, Piperacillin/tazobactam, Meropenem, Vancomycin
Ospedale San Carlo Borromeo, Associazione Oncologica Milanese AmoLaVita ONLUS
Severe Bacterial Infections
09/23
12/23
MargheRITA, NCT05260203: (Remote Intelligence for Therapeutic Adherence)

Completed
N/A
124
Europe
RITA (App)
Advice Pharma Group srl
Multiple Myeloma, Solitary Plasmacytoma, Amyloidosis, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, T Cell Non-Hodgkin Lymphoma, Lymphocytic Lymphoma, Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Acute Myeloid Leukemia, Myelodysplasia, Chronic Myeloproliferative Disorder, Treatment Adherence, Treatment Adherence and Compliance
01/23
01/23
NCT04673305: Cognitive Status Assessment In Elderly Patients With Active Treatment For Haematological Malignancies

Not yet recruiting
N/A
60
Europe
Cognitive Assessment, Cytokine dosage
Ospedale San Carlo Borromeo, Associazione Oncologica Milanese AmoLaVita ONLUS
Cognitive Impairment, Haematological Malignancy, Chemo-brain
03/23
09/23
MY MYELOMA, NCT05001087: A "physician & Patient-powered" Cohort Registry

Recruiting
N/A
1900
Europe
Observation
Fondazione EMN Italy Onlus, Amgen, GlaxoSmithKline Research & Development Limited, Janssen-Cilag S.p.A., Sanofi, Takeda, Bristol-Myers Squibb
Multiple Myeloma
03/27
03/27
Lucchini, Elisa
FIL_RICCO, NCT06835530: A Combination of Rituximab and CC-99282 As Front-line Therapy for Older Frail Patients with Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated with a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Not yet recruiting
2
47
Europe
Rituximab + Golcadomide (CC-99282)
Fondazione Italiana Linfomi - ETS
Diffuse Large B Cell Non-Hodgkin Lymphoma
04/30
04/30
NCT05819528: Primary Cardiac Lymphoma: Italian Multicenter Experience

Recruiting
N/A
43
Europe
Fondazione Italiana Linfomi - ETS
Primary Cardiac Lymphoma
04/26
06/26
FIL_MIMYC, NCT06588205: Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma

Not yet recruiting
N/A
200
Europe
Fondazione Italiana Linfomi - ETS
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
12/27
12/27
ZanOs, NCT06823960: Study to Assess Effectiveness and Safety of Zanubrutinib for Patients with Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

Recruiting
N/A
59
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Marginal Zone Lymphoma(MZL)
06/25
06/25
NCT05694325: Biologic Characterization of Patients With ITP

Recruiting
N/A
200
Europe
peripheral blood and bone marrow withdrawal
Gruppo Italiano Malattie EMatologiche dell'Adulto
Immune Thrombocytopenia
11/26
11/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zaja, Francesco
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Hourglass May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL
Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting
3
300
Europe, RoW
R-pola-mini-CHP, R-mini-CHOP
Nordic Lymphoma Group, Roche Pharma AG
DLBCL, Diffuse Large B Cell Lymphoma
12/25
12/28
NCT04168502 / 2019-003871-20: Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

Recruiting
3
414
Europe
Gemtuzumab Ozogamicin
Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Pfizer S.R.L.
Acute Myeloid Leukemia
04/25
04/27
BRUIN CLL-321, NCT04666038: Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
05/25
08/26
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
05/25
04/27
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
NCT03552692 / 2017-004630-29: Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma

Terminated
2
22
Europe
Venetoclax, ABT-199/GDC-0199
Fondazione Italiana Linfomi - ETS
T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory
03/20
02/23
FIL_KLIMT, NCT03891355 / 2018-000540-25: Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL

Active, not recruiting
2
16
Europe
Carfilzomib, Lenalidomide, Dexamethasone
Fondazione Italiana Linfomi ONLUS, CELGENE, AMGEN
Mantle Cell Lymphoma
12/20
12/22
NCT04251065 / 2018-002644-91: Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH

Terminated
2
8
Europe
Daratumumab, Darzalex
Fondazione Italiana Linfomi - ETS, Janssen
Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma
12/21
11/22
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Active, not recruiting
2
75
Europe
Ibrutinib, IMBRUVICA (commercial name)
Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.
DLBCL
07/24
07/27
Phoenix, NCT05924100 / 2021-001538-20: Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD

Recruiting
2
22
Europe
Luspatercept Injection [Reblozyl]
Associazione Qol-one, Celgene BMS
Myelodysplastic Syndromes, Del(5Q), Anemia, Transfusion-dependent Anemia
12/24
12/29
MALIBU, NCT03697512 / 2018-002364-44: Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

Active, not recruiting
2
175
Europe
Ibrutinib, Rituximab
International Extranodal Lymphoma Study Group (IELSG), Janssen-Cilag AG, F. Hoffmann La Roche Ltd, Janssen Pharmaceutica NV
Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma
06/27
06/27
NCT04278924 / 2019-004103-12: A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

Completed
2
41
Europe, Japan, US, RoW
Placebo, TAK-079
Takeda
Primary Immune Thrombocytopenia
04/24
04/24
FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

Recruiting
2
49
Europe
Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C)), Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)
Fondazione Italiana Linfomi - ETS
Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
04/26
04/29
EPCORE DLBCL-3, NCT05660967 / 2021-005744-29: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Recruiting
2
180
Europe, Japan, US, RoW
Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid®
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
01/26
07/27
TALIM, NCT06880601: Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma

Not yet recruiting
2
52
NA
Teclistamab
Gruppo Italiano Malattie EMatologiche dell'Adulto
Multiple Myleoma, Multiple Myeloma in Relapse, Multiple Myeloma Refractory
11/29
11/29
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Withdrawn
2
150
Europe
R-DHAP, Pola-R-DHAP
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
01/29
01/29
FIL_A-BEGEV, NCT05300282: Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

Recruiting
1/2
122
Europe
Atezolizumab, BEGEV, Bendamustine, Gemcitabine, Vinorelbine
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Relapsed or Refractory Hodgkin's Lymphoma
04/27
04/30
NCT04454580: Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy

Recruiting
N/A
15
Europe
Venetoclax, Azacitidine, Decitabine
Ospedale Maggiore Di Trieste
Acute Myeloid Leukemia, Adult, Hypomethylating Agents, Venetoclax
09/20
09/20
ICI-RT-1, NCT04419441: Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma

Recruiting
N/A
12
Europe
Immune checkpoint inhibitor, radiotherapy
Ospedale Maggiore Di Trieste
Hodgkin Lymphoma, Immune Checkpoint Inhibitor, Radiotherapy
09/20
09/20
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting
N/A
250
Europe
Ospedale di Circolo - Fondazione Macchi
SARS-CoV-2 Infection, Hematological Malignancies
10/22
10/22
ITP0918, NCT03465020: Investigation on a Dynamic Cohort of Italian Patients With Active ITP

Recruiting
N/A
861
Europe
Observation
Gruppo Italiano Malattie EMatologiche dell'Adulto, Hematology Project Foundation
Idiopathic Thrombocytopenic Purpura
07/23
07/23
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Recruiting
N/A
80
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
03/25
03/25
GIMEMA, NCT04867915: Study on the Diagnosis and Management of CLL in Italy by

Recruiting
N/A
12500
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, MBL-CLL - Monoclonal B-Cell Lymphocytosis Chronic Lymphocytic Leukaemia-Type
10/26
10/26
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting
N/A
1500
Europe
"novel" MAB (alone or in combination)
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Non-Hodgkin Lymphoma, B-cell
10/38
10/38
Fozza, Claudio
NCT04168502 / 2019-003871-20: Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

Recruiting
3
414
Europe
Gemtuzumab Ozogamicin
Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Pfizer S.R.L.
Acute Myeloid Leukemia
04/25
04/27
ACROBAT, NCT04184505 / 2019-003997-25: Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS

Recruiting
3
274
Europe
Azacitidine, AZA, Standard Chemotherapy, STD CHT, Allogeneic stem cell transplantation, HSCT
Gruppo Italiano Malattie EMatologiche dell'Adulto, AIFA - Italian Medicines Agency, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus
High-risk MDS
03/24
03/24
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
1621-QLG-LG, NCT03755856: Long-term Outcomes for Acute Myeloid Leukemia Patients

Recruiting
N/A
343
Europe, RoW
Questionnaire
Gruppo Italiano Malattie EMatologiche dell'Adulto, European Organisation for Research and Treatment of Cancer - EORTC
Acute Myeloid Leukemia
06/21
12/22
CML1012, NCT01752062: Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors

Recruiting
N/A
148
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Myeloid Leukemia, Pregnancy
12/22
12/22
GIMEMA 2320, NCT04589728: Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96

Recruiting
N/A
104
Europe
Venetoclax plus HMA
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia
12/22
12/23
NCT05819528: Primary Cardiac Lymphoma: Italian Multicenter Experience

Recruiting
N/A
43
Europe
Fondazione Italiana Linfomi - ETS
Primary Cardiac Lymphoma
04/26
06/26
NCT04627090: LCH in Adults: a Collaborative, Prospective-retrospective, Observational Study

Recruiting
N/A
186
Europe
Data collection
Gruppo Italiano Malattie EMatologiche dell'Adulto
Langerhans Cell Histiocytosis
03/24
03/24
NCT04460950: Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms

Recruiting
N/A
237
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia, Familial Acute Myeloid Leukemia, Myelodysplastic Syndromes
03/25
03/25
CLARITY, NCT03190525: Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma

Recruiting
N/A
520
Europe
Quality of life questionnaires
Gruppo Italiano Malattie EMatologiche dell'Adulto
Multiple Myeloma
12/24
12/24
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting
N/A
1500
Europe
"novel" MAB (alone or in combination)
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Non-Hodgkin Lymphoma, B-cell
10/38
10/38
Arcari, Annalisa
RENOIR, NCT02390869 / 2012-003392-18: Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

Active, not recruiting
3
128
Europe
R2-MANT, Rituximab and Lenalidomide (R2), R-MANT, Rituximab (R)
Fondazione Italiana Linfomi - ETS
Lymphoma, Follicular
01/23
08/27
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
FIL_Copa-RB, NCT04433182 / 2019-004898-63: Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

Terminated
2
37
Europe
Copanlisib, ALIQOPA
Fondazione Italiana Linfomi - ETS
Diffuse Large B-cell Lymphoma
12/24
12/24
FIORELLA, NCT03495960 / 2016-003116-12: Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System

Completed
2
72
Europe
Rituximab, Methotrexate, Procarbazine, Lenalidomide, Radiotherapy, Temozolomide
International Extranodal Lymphoma Study Group (IELSG)
Primary Central Nervous System Lymphoma
12/24
12/24
FIL_MOZART, NCT06492837: Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Not yet recruiting
2
56
Europe
Mosunetuzumab in combination with Zanubrutinib, LUNSUMIO in combination with BRUSINKA
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
09/28
09/33
EPCORE DLBCL-3, NCT05660967 / 2021-005744-29: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Recruiting
2
180
Europe, Japan, US, RoW
Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid®
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
01/26
07/27
FIL_RICCO, NCT06835530: A Combination of Rituximab and CC-99282 As Front-line Therapy for Older Frail Patients with Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated with a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Not yet recruiting
2
47
Europe
Rituximab + Golcadomide (CC-99282)
Fondazione Italiana Linfomi - ETS
Diffuse Large B Cell Non-Hodgkin Lymphoma
04/30
04/30
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Withdrawn
2
150
Europe
R-DHAP, Pola-R-DHAP
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
01/29
01/29
LH_BIO, NCT06822855: Changing Paragidms in the Prognostic Assessment of Hodgkin Lymphoma

Recruiting
N/A
755
Europe
Azienda Unità Sanitaria Locale Reggio Emilia
Classical Hodgkin Lymphoma, Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory
12/26
12/26
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Recruiting
N/A
80
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
03/25
03/25
NCT06156774: SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

Recruiting
N/A
130
Europe
Chimeric Antigen Receptor T-cells (CAR-T) therapy
Fondazione Italiana Linfomi - ETS, Kite, A Gilead Company
Non-hodgkin Lymphoma,B Cell
07/26
07/26
FIL_FOLL-BIO, NCT05816850: Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial

Recruiting
N/A
654
Europe
EZH2 mutations/CNAs by droplet digital PCR (ddPCR), EZH2-derived gene expression signature by RNA-Seq
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
06/25
06/26
NCT05524298: Quality of Life on Elderly Patients with Low Grade Non-Hodgkin Lymphoma

Recruiting
N/A
150
Europe
Fondazione Italiana Linfomi - ETS
Low Grade Non-Hodgkin's Lymphoma, Adult
02/25
02/25
NCT03552003: Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis

Recruiting
N/A
400
Europe
Treatment for clinical practise
Fondazione Italiana Linfomi ONLUS
Classical Hodgkin Lymphoma
01/26
01/26
NCT05934084: Lifestyles Implemented-Survivorship Care Plan in Lymphoma Survivors

Recruiting
N/A
552
Europe
Lifestyles Implemented-Survivorship Care Plan (LS-SCP)
Fondazione Italiana Linfomi - ETS
Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL)
02/26
02/26
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting
N/A
1500
Europe
"novel" MAB (alone or in combination)
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Non-Hodgkin Lymphoma, B-cell
10/38
10/38
Ferreri, Andres
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Hourglass May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL
Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting
3
300
Europe, RoW
R-pola-mini-CHP, R-mini-CHOP
Nordic Lymphoma Group, Roche Pharma AG
DLBCL, Diffuse Large B Cell Lymphoma
12/25
12/28
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
05/25
04/27
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Active, not recruiting
2
75
Europe
Ibrutinib, IMBRUVICA (commercial name)
Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.
DLBCL
07/24
07/27
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Active, not recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
01/25
07/29
NCT06854653: A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

Recruiting
2
115
Europe, US, RoW
PTX-100
Prescient Therapeutics, Ltd.
CTCL
01/28
06/28
ALPHA-2, NCT04416984: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Recruiting
1/2
160
Europe, Canada, US, RoW
ALLO-501A, ALLO-647, Fludarabine, Cyclophosphamide
Allogene Therapeutics
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
01/25
05/29
2018-523-00US1, NCT03779113: An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

Active, not recruiting
1
140
Europe, US
HMPL-523
Hutchmed
Non Hodgkin Lymphoma
12/24
01/26
NCT05365659: IKS03 in Patients with Advanced B Cell Non-Hodgkin Lymphomas

Recruiting
1
140
Europe, Canada, US, RoW
IKS03
Iksuda Therapeutics Ltd.
B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, B-cell Lymphoma
09/25
09/27
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Recruiting
N/A
80
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
03/25
03/25
NCT06156774: SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

Recruiting
N/A
130
Europe
Chimeric Antigen Receptor T-cells (CAR-T) therapy
Fondazione Italiana Linfomi - ETS, Kite, A Gilead Company
Non-hodgkin Lymphoma,B Cell
07/26
07/26
Montefusco, Vittorio
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
DEDALO, NCT04124497 / 2018-002090-21: A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients

Active, not recruiting
2
45
Europe
Daratumumab, Darzalex, Pomalidomide, Imnovid, Dexamethasone
Fondazione EMN Italy Onlus, Janssen Pharmaceutica NV, Celgene International II
Multiple Myeloma, Deletion 17P Syndrome
07/25
07/25
NCT06682637: Melflufen for Elderly Patients With Relapsed Myeloma

Withdrawn
2
30
Europe
Melflufen, Dexamethasone
Fondazione EMN Italy Onlus
Relapse Multiple Myeloma
03/25
03/25
TAID, NCT04816968: Antibiotics Continuous Infusion at Home

Not yet recruiting
1
50
Europe
Cefepime, Piperacillin/tazobactam, Meropenem, Vancomycin
Ospedale San Carlo Borromeo, Associazione Oncologica Milanese AmoLaVita ONLUS
Severe Bacterial Infections
09/23
12/23
MargheRITA, NCT05260203: (Remote Intelligence for Therapeutic Adherence)

Completed
N/A
124
Europe
RITA (App)
Advice Pharma Group srl
Multiple Myeloma, Solitary Plasmacytoma, Amyloidosis, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, T Cell Non-Hodgkin Lymphoma, Lymphocytic Lymphoma, Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Acute Myeloid Leukemia, Myelodysplasia, Chronic Myeloproliferative Disorder, Treatment Adherence, Treatment Adherence and Compliance
01/23
01/23
NCT04673305: Cognitive Status Assessment In Elderly Patients With Active Treatment For Haematological Malignancies

Not yet recruiting
N/A
60
Europe
Cognitive Assessment, Cytokine dosage
Ospedale San Carlo Borromeo, Associazione Oncologica Milanese AmoLaVita ONLUS
Cognitive Impairment, Haematological Malignancy, Chemo-brain
03/23
09/23
MY MYELOMA, NCT05001087: A "physician & Patient-powered" Cohort Registry

Recruiting
N/A
1900
Europe
Observation
Fondazione EMN Italy Onlus, Amgen, GlaxoSmithKline Research & Development Limited, Janssen-Cilag S.p.A., Sanofi, Takeda, Bristol-Myers Squibb
Multiple Myeloma
03/27
03/27
Lucchini, Elisa
FIL_RICCO, NCT06835530: A Combination of Rituximab and CC-99282 As Front-line Therapy for Older Frail Patients with Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated with a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Not yet recruiting
2
47
Europe
Rituximab + Golcadomide (CC-99282)
Fondazione Italiana Linfomi - ETS
Diffuse Large B Cell Non-Hodgkin Lymphoma
04/30
04/30
NCT05819528: Primary Cardiac Lymphoma: Italian Multicenter Experience

Recruiting
N/A
43
Europe
Fondazione Italiana Linfomi - ETS
Primary Cardiac Lymphoma
04/26
06/26
FIL_MIMYC, NCT06588205: Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma

Not yet recruiting
N/A
200
Europe
Fondazione Italiana Linfomi - ETS
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
12/27
12/27
ZanOs, NCT06823960: Study to Assess Effectiveness and Safety of Zanubrutinib for Patients with Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

Recruiting
N/A
59
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Marginal Zone Lymphoma(MZL)
06/25
06/25
NCT05694325: Biologic Characterization of Patients With ITP

Recruiting
N/A
200
Europe
peripheral blood and bone marrow withdrawal
Gruppo Italiano Malattie EMatologiche dell'Adulto
Immune Thrombocytopenia
11/26
11/26

Download Options